As previously reported, the reduction of inflammation may be related to weight loss, that was significant in the different outcome trials, going from a 0.6-kg reduction at 12 weeks with Lixisenatide in ELIXA trial to 4.3 kg at 2 years with injectable semaglutide in SUSTAIN-6 trial [25, 26]
DiMartino SJ, Gao H, Eng S, Valenzuela G, Fuerst T, Emeremni C, et al
GLP-1s have been shown to aid in weight reduction in obese patients with and without diabetes through improved glycemic control via stimulating insulin and inhibiting glucagon
In SURPASS-2, all three tirzepatide doses delivered superior A1C and body weight reductions from baseline compared to semaglutide
vitamin 95 for one session for glutathione shot